PR
    Pharmacy Remedy

    Immunotherapy (Checkpoint Inhibitors)

    Blincyto (blinatumomab) in Kuwait — Regulatory and Supply Information

    CD19-directed CD3 bispecific T-cell engager (BiTE) for B-cell precursor acute lymphoblastic leukemia (ALL) — MRD-positive first remission, relapsed / refractory Ph-negative ALL, and Ph-positive ALL after ≥2 TKIs. Given as continuous 28-day IV infusion per cycle (9 or 28 mcg/day, weight-dependent in pediatrics).

    Blincyto (blinatumomab) original manufacturer carton

    Prescription-only medicine. No pricing is published on this page. Prescription-medicine pricing is not advertised to the public in this market.

    This page is informational and is not an advertisement, a promotional communication, or medical advice. It does not offer any medicine for sale to the public. Treatment decisions belong to your treating physician.

    What this medicine is

    Active ingredient
    blinatumomab
    Marketing authorisation holder
    Amgen
    Therapeutic class
    Immunotherapy (Checkpoint Inhibitors)

    Presentations and dosage forms

    • 35 mcg powder for solution for infusion (with IV stabilizer)

    Storage, cold chain and handling

    Refrigerate 2–8°C, protect from light, do not freeze. Reconstituted infusion bags stable up to 10 days at 2–8°C with IV stabilizer.

    The regulatory position in Kuwait

    Medicines in Kuwait are regulated by the Ministry of Health. This page is informational and is not an advertisement.

    Ministerial Decision No. 9/2025, effective 15 January 2025, requires prior authorisation from the Drug Inspection Department for all advertising of pharmacies, medicines and health products, and states explicitly that this includes websites and social media. It provides that the pricing of health products may not be displayed without approval, that promoting discounts or offers requires authorisation, and that superlatives are not permitted. Penalties reach KD 3,000 and up to three years' imprisonment.

    For that reason this page carries no pricing, no offer and no promotional description of any medicine. It sets out what the medicine is, how it is presented and handled, and which authority to approach.

    We have not verified Kuwait's personal-import procedure from a primary source. Confirm the applicable requirements directly with the Ministry of Health before acting on anything described here.

    We have not verified Kuwait's personal-import procedure. We do not describe one here. Confirm the current requirements with the Ministry of Health.

    Documentation typically required

    • A valid prescription from the treating physician
    • A medical report describing the diagnosis and the treatment plan
    • Proof of identity for the patient
    • For a hospital or clinic: the establishment licence and the request of the responsible pharmacist

    Official sources

    Search terms for this medicine

    The same molecule is searched under several names. All of the following refer to the same product:

    • Blincyto
    • blinatumomab
    • بلينسايتو
    • بلاناتوموماب
    • Blincyto Kuwait
    • بلينسايتو الكويت
    • blinatumomab MOH Kuwait
    • Blincyto prescription
    • بلينسايتو وصفة طبية

    Frequently asked questions

    Prescription-based enquiry

    If you hold a valid prescription from a treating physician in Kuwait, you can send us the prescription details and we will reply with the regulatory and documentation position for that specific product. We do not publish pricing for Kuwait and we do not sell to the public.

    Send a prescription-based enquiry

    Background reading

    Related medicines

    Medically reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-07-29 · Ministry of Health — Drug Inspection Department

    For healthcare professionals

    Prescribers, hospital and specialty pharmacies, oncology centres and procurement departments: named patient supply, documentation and the sourcing workflow.